David E. Nichols

David Earl Nichols (born December 23, 1944, Covington, Kentucky) is an American pharmacologist and medicinal chemist.[1] Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969.His contributions include the synthesis and reporting of escaline, LSZ, 6-APB, 2C-I-NBOMe and other NBOMe variants (NBOMe-2C-B, NBOMe-2C-C, NBOMe-2C-D), and several others, as well as the coining of the term "entactogen".Nichols has said that he believes gray-market chemists used information from papers he published on 4-methylthioamphetamine (MTA) in the 1990s to synthesize the drug, which they sold in tablets nicknamed "flatliners" as a substitute for MDMA (Ecstasy).[8] Several deaths have been attributed to compounds that have been discovered in Nichols' lab, which he finds quite upsetting, "I was stunned by this revelation, and it left me with a hollow and depressed feeling for some time.
Covington, Kentucky5-HT2A receptordopamine receptorshallucinogensMDMA neurotoxicityMedicinal ChemistryPharmacologyPurdue UniversityIndiana University School of MedicineAmericanpharmacologistmedicinal chemistpsychoactiveisomershallucinogenicamphetaminesescaline2C-I-NBOMeNBOMe-2C-BNBOMe-2C-CNBOMe-2C-DentactogenHeffter Research InstituteGermanArthur HefftermescalinepeyoteSerotoninpsychedelicsWest Lafayette, INUniversity of CincinnatiUniversity of IowaPostdoc WorkStructure-activity relationshipPIHKALradioligandETH-LADPRO-LADAL-LADTiHKALpsilocybin5-methyl-MDA4-methylthioamphetaminedopamineligandsdihydrexidinedinapsolineParkinson's diseasedinoxylineschizophreniaDesigner druggrey marketAlexander ShulginCharles D. NicholsPeyton Jacob IIIDaniel TrachselJonathan OttJason WallachAdam HalberstadtMatthew J. BaggottRick StrassmanCasey William HardisonBromo-DragonFLY25I-NBOMeLysergic acid 2,4-dimethylazetidideWayback MachineSullum, JacobReasonThe Wall Street JournalNatureBibcode